These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35060347)

  • 1. The microRNA-204-5p inhibits APJ signalling and confers resistance to cardiac hypertrophy and dysfunction.
    Gaddam RR; Kim YR; Jacobs JS; Yoon JY; Li Q; Cai A; Shankaiahgari H; London B; Irani K; Vikram A
    Clin Transl Med; 2022 Jan; 12(1):e693. PubMed ID: 35060347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APJ acts as a dual receptor in cardiac hypertrophy.
    Scimia MC; Hurtado C; Ray S; Metzler S; Wei K; Wang J; Woods CE; Purcell NH; Catalucci D; Akasaka T; Bueno OF; Vlasuk GP; Kaliman P; Bodmer R; Smith LH; Ashley E; Mercola M; Brown JH; Ruiz-Lozano P
    Nature; 2012 Aug; 488(7411):394-8. PubMed ID: 22810587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage.
    Sato T; Sato C; Kadowaki A; Watanabe H; Ho L; Ishida J; Yamaguchi T; Kimura A; Fukamizu A; Penninger JM; Reversade B; Ito H; Imai Y; Kuba K
    Cardiovasc Res; 2017 Jun; 113(7):760-769. PubMed ID: 28371822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition.
    Parikh VN; Liu J; Shang C; Woods C; Chang AC; Zhao M; Charo DN; Grunwald Z; Huang Y; Seo K; Tsao PS; Bernstein D; Ruiz-Lozano P; Quertermous T; Ashley EA
    Am J Physiol Heart Circ Physiol; 2018 Aug; 315(2):H348-H356. PubMed ID: 29775410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of microRNA-23b-5p in the promotion of cardiac hypertrophy and dysfunction via the HMGB2 signaling pathway.
    Boureima Oumarou D; Ji H; Xu J; Li S; Ruan W; Xiao F; Yu F
    Biomed Pharmacother; 2019 Aug; 116():108977. PubMed ID: 31103821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long non-coding RNA cardiac hypertrophy-associated regulator governs cardiac hypertrophy via regulating miR-20b and the downstream PTEN/AKT pathway.
    Zhang M; Jiang Y; Guo X; Zhang B; Wu J; Sun J; Liang H; Shan H; Zhang Y; Liu J; Wang Y; Wang L; Zhang R; Yang B; Xu C
    J Cell Mol Med; 2019 Nov; 23(11):7685-7698. PubMed ID: 31465630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apelin/APJ system: A bifunctional target for cardiac hypertrophy.
    Lu L; Wu D; Li L; Chen L
    Int J Cardiol; 2017 Mar; 230():164-170. PubMed ID: 27979574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-17-5p Promotes Cardiac Hypertrophy by Targeting Mfn2 to Inhibit Autophagy.
    Xu X; Su YL; Shi JY; Lu Q; Chen C
    Cardiovasc Toxicol; 2021 Sep; 21(9):759-771. PubMed ID: 34120306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gαi-biased apelin analog protects against isoproterenol-induced myocardial dysfunction in rats.
    Coquerel D; Delile E; Dumont L; Chagnon F; Murza A; Sainsily X; Salvail D; Sarret P; Marsault E; Auger-Messier M; Lesur O
    Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1646-H1656. PubMed ID: 33635165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y mediates cardiac hypertrophy through microRNA-216b/FoxO4 signaling pathway.
    Wang J; Hao D; Zeng L; Zhang Q; Huang W
    Int J Med Sci; 2021; 18(1):18-28. PubMed ID: 33390770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology.
    Hirt MN; Werner T; Indenbirken D; Alawi M; Demin P; Kunze AC; Stenzig J; Starbatty J; Hansen A; Fiedler J; Thum T; Eschenhagen T
    J Mol Cell Cardiol; 2015 Apr; 81():1-9. PubMed ID: 25633833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of APJ mediated β-arrestin signalling improves high-fat diet induced metabolic dysfunction but does not alter cardiac function in mice.
    Li N; Ma X; Ban T; Xu S; Ma Y; Ason B; Hu LA
    Biochem J; 2020 Sep; 477(17):3313-3327. PubMed ID: 32779693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Silencing of circHIPK3 Inhibits Pressure Overload-Induced Cardiac Hypertrophy and Dysfunction by Sponging miR-185-3p.
    Xu X; Wang J; Wang X
    Drug Des Devel Ther; 2020; 14():5699-5710. PubMed ID: 33402817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Qiliqiangxin Attenuates Phenylephrine-Induced Cardiac Hypertrophy through Downregulation of MiR-199a-5p.
    Zhang H; Li S; Zhou Q; Sun Q; Shen S; Zhou Y; Bei Y; Li X
    Cell Physiol Biochem; 2016; 38(5):1743-51. PubMed ID: 27161004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-26a-5p alleviates cardiac hypertrophy and dysfunction via targeting ADAM17.
    Shi H; Li H; Zhang F; Xue H; Zhang Y; Han Q
    Cell Biol Int; 2021 Nov; 45(11):2357-2367. PubMed ID: 34370360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SP1-induced SNHG14 aggravates hypertrophic response in in vitro model of cardiac hypertrophy via up-regulation of PCDH17.
    Long Y; Wang L; Li Z
    J Cell Mol Med; 2020 Jul; 24(13):7115-7126. PubMed ID: 32436661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-338-5p ameliorates pathological cardiac hypertrophy by targeting CAMKIIδ.
    Li K; Lin Y; Li C
    Arch Pharm Res; 2019 Dec; 42(12):1071-1080. PubMed ID: 31820396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors.
    Ganesan J; Ramanujam D; Sassi Y; Ahles A; Jentzsch C; Werfel S; Leierseder S; Loyer X; Giacca M; Zentilin L; Thum T; Laggerbauer B; Engelhardt S
    Circulation; 2013 May; 127(21):2097-106. PubMed ID: 23625957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Apelin-Apelin Receptor Axis Triggers Cholangiocyte Proliferation and Liver Fibrosis During Mouse Models of Cholestasis.
    Chen L; Zhou T; White T; O'Brien A; Chakraborty S; Liangpunsakul S; Yang Z; Kennedy L; Saxena R; Wu C; Meng F; Huang Q; Francis H; Alpini G; Glaser S
    Hepatology; 2021 Jun; 73(6):2411-2428. PubMed ID: 32964473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro and In Vivo Evaluation of a Small-Molecule APJ (Apelin Receptor) Agonist, BMS-986224, as a Potential Treatment for Heart Failure.
    Gargalovic P; Wong P; Onorato J; Finlay H; Wang T; Yan M; Crain E; St-Onge S; Héroux M; Bouvier M; Xu C; Chen XQ; Generaux C; Lawrence M; Wexler R; Gordon D
    Circ Heart Fail; 2021 Mar; 14(3):e007351. PubMed ID: 33663236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.